Website is intended for physicians
Search:

 

Abstract:

To evaluate the extent and distribution of focal fibrosis by delayed contrast-enhanced magnetic resonance imaging (DCE MRI) in patients with severe left ventricle hypertrophy caused by genetically determined hypertrophy cardiomyopathy (HCP) and compare it with global and regional myocardial function. 15 patients with HCP were studied using 1,5 T MR-scanner (Avanto, Siemens Medical Solution). 80% patients with HCP had foci of delayed CE, which were predominantly located in the anteroseptal. 33% patients with HCP had foci of perfusion defects. Septal walls with DCE foci were significantly thicker than non-enhanced segments (19,0±6,4 and 10,6±4,7, p < 0,001). Significant correlations were observed between end-diastolic segment's thickness and extent of DCE (r = 0,26, p < 0,05). Significant reverse correlation was found between extent of contrast enhancement and stroke volume in patients with HCP (r = -0,57, r < 0,05). Mean volume DCE regions was 18,4±8,5 cm3 (Mean±SE), maximum volume of hyperenhanced area was 127,9 cm3. Abnormal signal intensity from first-pass myocardial perfusion correlates with the delayed enhancement foci in patients with HCM. The extent of focal scarring in patients with HCP may reflect the severity of myocardial damage associated with the regional hypertrophy and hypokinesia of these segments.

 

Reference 

 

1.     Report of the 1995 WHO/IFSC. Task force of the definition and classification of cardiomyopathies. Circulation. 1996; 93: 841-889.

 

 

2.     Elliott P., Sharma S. et al. Survival agter cardiac arrestor sustained ventricular tachycardia in ptc with hypertrophic cardiomyopathy. JACC. 1999; 33: 1596-1601.

 

 

3.     Maron B.J. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002; 287: 1308-1320.

 

 

4.     Maron B.J. Hypertrophic cardiomyopathy and suddendeath: new perspectives on risk stratification and prevention with implantable cardioverter-defibrillator. Eur.Heart.J. 2000; 201: 1979-1983.

 

 

5.     Maron B.J., Epstein S.E., Roberts Wc. Hypertrophic cardiomyopathy and transmural myocardial infarction without signicant atherosclerosis of the extramural coronary arteries. Am. J. Cardiol. 1979; 43: 1086-1102.

 

 

6.     Tanaka M., Fujiwara H., Onodera E. et al. Quantitative analysis of myocardioal fibrosis in normal, hypertensive hearts and hypertrophic cardiomyopathy. Br.Heart. J. 1986; 55: 575-581.

 

 

7.     Rickers K., Wilke N., Jerosh-Herold M. et al. Utiliye of magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005; 112:855-861.

 

 

8.     Gupta A., Lee V.S., Chung Y.C. et al. Myocardial in arction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology. 2004;   233:1001-1004.

 

 

9.     Kuhl H.P., Papavasiliu T.S., Beek A.M. et al. Myocardial viability: rapid assessment with delayed contrast-enhanced MR imaging with three-dimensional inversion-recovery prepared pulse sequence. Radiology. 2004; 230:576-582.

 

 

10.   Moon J., Reed E., Sheppard M. et al.The histologic basis of late enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy.JACC. 2 004; 43: 2260-2264.

 

 

11.   Беленков Ю.Н., Терновой С.К., Синицын В.Е. Магнитно-резонансная томография сердца и сосудов. М.: Видар. 1998.

 

 

12.   Simonetti O.P., Kim R.J., Fieno D.S., Hillenbrand H.B.,Wu E., Bundy J.M., Finn J.P., Judd R.M. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001; 218: 215-223.

 

 

13.   Cerqueira M.D., Weissman N.J., Dilsizian V. et al. Standardised myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation. 2002;105: 539-542.

 

 

14.   Choudhury L., Mahrholdt H., Wagner A., Choi K.M.,Elliott M.D., Klocke F.J., Bonow R.O., Judd R.M., Kim R J. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J.Am. Coll. Cardiol. 2002; 40: 2156-2164.

 

 

15.   Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M.,Smith G.C., Pennell D J.Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2003; 41: 1561-1567.

 

 

16.   Debl K., Djavidani B., Buchner S., Lipke C., Nitz W., Feuerbach S., Riegger G., Luchner A. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart. 2006; 92: 1447-1451.

 

17.   Dumont C.A., Monserrat L., Soler R., Rodriguez E.,Fernandez X., Peteiro J., Bouzas B., Pinon P., Castro-Beiras A. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance inpatients with hypertrophic cardiomyopathy. Rev. Esp.Cardiol. 2007; 60: 15-23.

ANGIOLOGIA.ru (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы